ADARx Prices $446.3 Million Nasdaq IPO, Extending Biotech's Run
ADARx Pharmaceuticals priced a $446.3 million Nasdaq IPO, one of the largest biotech debuts this cycle and the latest sign that the life-sciences listing window has reopened.
Topic
Nasdaq
Topic
Nasdaq
Nasdaq Closes at Second Straight Record as Oil Slides and Trump Delays Iran Deal
The Nasdaq logged a second straight record close as oil fell on Iran's Hormuz offer. Meta's Muse added $192 billion in market cap…
Oura Targets $15.6 Billion Valuation in Nasdaq IPO Debut
Oura's Nasdaq IPO targets up to $15.6 billion fully diluted, backed by 121% subscription growth, $60.8 million net income and a $…
Crude's Slide to 3-Week Low Lifts Tech Shares as Stocks Extend Gains
WTI crude fell over 2% to a 3-week low on Iran's Strait of Hormuz proposal, lifting the S&P 500 to a 5-week high and sending chip…
Iambic Therapeutics Files for U.S. IPO on Nasdaq
Iambic Therapeutics has filed for a U.S. IPO, joining the queue of AI drug-discovery startups targeting a Nasdaq listing and test…